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Cannabinoid agonist WIN-55,212-2 partially restores
neurogenesis in the aged rat brain
Molecular Psychiatry (2009) 14, 1068–1069; doi:10.1038/
mp.2009.62
A decline in neurogenesis in the hippocampus may
underlie age-related memory impairment in rats and
humans. We now show that WIN 55,212-2 administra-
tion for 3 weeks can partially restore neurogenesis in
the hippocampus of aged rats. Cannabinoid receptor
stimulation therapy may thus provide clinical benefit
for humans with age-associated memory impairment.
The endocannabinoid system regulates some as-
pects of the brain’s inflammatory response, including
Figure 1 (A) Doublecortin immunoreactivity (IR) in the dentate gyrus (DG). For all pictures, Doublecortin immunoreactivity
(DCX-IR) is in green and NeuN-IR is in red. (a, b) 3-month-young rats, magnification  600. (c, d) 23-month control rats,
magnification  600. (e, f) 23-month-old rats treated for 3 weeks with 2mgkg
 1 per day of WIN-55,212-2, magnification
 600. Note the significant decrease in DCX-IR between young (a, b) and aged control (c, d) rats, as well as the significant
increase in DCX-IR between aged controls (c, d) and WIN-treated aged (e, f) rats. (B) Number of DCX-IR cells by DG: a
significant increase (116%, *P<0.05, Fisher’s PLSD post-hoc test) of doublecortin immunoreactive cells was observed in the
subgranular zone of the dentate gyrus of rats treated 3 weeks with 2mgkg
 1 per day of WIN-55,212-2. (C) 5-bromo-2-
deoxyuridine (BrdU)-positive cells in the DG of aged animals: a significant increase (63%, *P<0.05, Fisher’s PLSD post-hoc
test) of BrdU immunoreactive cells was observed in the subgranular zone of the dentate gyrus of rats treated for 3 weeks with
2mgkg
 1 per day of WIN-55,212-2. (D) Proportion of neurons/glia co-localized with BrdU cells in the DG of aged animals: no
significant changes could be seen in the proportion of new neurons over new glial cells.
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ulation of microglial activation.
1–4 The endo-
cannabinoid system is composed of two G-protein-
coupled receptors designated as CB1 and CB2 ex-
pressed throughout the body and notably by neural
stem cells.
5 We have previously shown that stimula-
tion of the CB1/2 receptors using a low dose of
WIN-55,212-2 significantly reversed the LPS-induced
microglia activation in young rats.
2 This anti-inflam-
matory effect was also found in aged rats, attenuating
the age-induced performance impairment observed in
the water pool task.
3 As normal aging is associated
with increased levels of microglial activation and a
decrease in neurogenesis, both probably contributing
to the hippocampus-related memory deficit, we in-
vestigated the effects of an agonist of CB1/2 receptors
on neurogenesis in the brain of normal aged rats.
A total of 12 old (23-month-old) and 6 young
(3-month-old) male F-344 rats were chronically
infused for 28 days subcutaneously using an osmotic
minipump with WIN-55,212-2 (2mgkg
 1 per day
n=6) or the vehicle (n=12) into the dorsal abdominal
area. Two injections of 50mgkg
 1 i.p. of 5-bromo-2-
deoxyuridine were made on day 1 and day 2 post
surgery to track new cells’ production. The rats were
assigned to one of the following three groups: young-
vehicle (n=6), oldþvehicle (n=6) and oldþWIN-
55,212-2 2mgkg
 1 per day (n=6).
Doublecortin immunoreactivity was found only in
the subgranular zone of the dentate gyrus (DG) of the
hippocampus (Figure 1A). A significant difference
(Figure 1Aa–d) in doublecortin immunoreactivity was
found between young (3-month-old, 73.125±22.8 cells
per DG) and old rats (23-month-old, 3±1.8 P<0.05).
The 4 weeks of WIN 55,212-2 infusion resulted in a
significant increase in doublecortin immunoreactivity
cells (þ116%, F1,30=6.774, P=0.0142, ANOVA with
Fisher’s PLSD post-hoc test) as compared with that in
old vehicle-treated controls (Figure 1B).
5-bromo-2-deoxyuridine immunoreactivity was
found sparsely in the cortex and hippocampus of the
old vehicle-treated controls. The number of 5-bromo-2-
deoxyuridine immunoreactivity cells was counted in
the DG; the 4 weeks of WIN-55,212-2 infusion produced
a significant increase in 5-bromo-2-deoxyuridine im-
munoreactivity cells (þ63%, F1,221=12.795, P=0.0004
ANOVA with Fisher’s PLSD post-hoc test) as compared
with that in old vehicle-treated controls (Figure 1C).
The proportion of newly produced neurons over glial
cells was determined and showed no significant
difference between control or treated aged rats (Figure
1D, P=0.42), confirming the increase in number of
neurons engrafted in the DG after the 4-week treatment.
Our results confirm that neurogenesis is still
present during normal aging in rats, although at a
drastically reduced level as compared with that in
young rats, for review see Verret et al.
6 We now report
that neurogenesis in aged rats can be significantly
increased by a low, continuous, non-psychoactive
dose of a cannabinoid receptor agonist, WIN-55,212-2.
This report shows for the first time the potential
therapeutic efficacy of endocannabinoid receptor
stimulation in stimulating neurogenesis from prolif-
eration to engraftment during normal aging in vivo.
The current results, coupled with our previous
observations regarding the role of endocannabinoid
receptors,
3,4 underscores the potential clinical bene-
fits of cannabinoid pharmacotherapies during normal
and pathological brain aging.
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Activation of brain
interleukin-1b in
schizophrenia
Molecular Psychiatry (2009) 14, 1069–1071; doi:10.1038/
mp.2009.52
The underlying pathophysiological cause of schizo-
phrenia is essentially unknown. Increasing evidence
suggests that immunological processes may contri-
bute to the etiology of the disease. Owing to the lack
of direct evidence of an infectious cause of schizo-
phrenia much attention has been directed towards
cytokines; molecules that initiate immunological
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